Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Last Name

    Julia V Johnson MD

    TitleChair and Professor
    InstitutionUniversity of Massachusetts Medical School
    DepartmentObstetrics and Gynecology
    AddressUMass Memorial Medical Center
    119 Belmont Street
    Worcester MA 01605
      Other Positions
      InstitutionUMMS - Graduate School of Biomedical Sciences
      DepartmentMasters in Clinical Investigation


        ResearchJulia Johnson

        • Neurocrine Biosciences, Inc. "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects with Endometriosis." 11/07 - 12/08.
        • Bayer Pharmaceutical."Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age." 10/07 - 11/08.
        • Bayer Pharmaceutical."A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq (drospirenone 0.5 mg/17ß-estradiol 0.5 mg,
          drospirenone 0.25 mg/17ß-estradiol 0.5 mg, and J.Johnson
          17ß-estradiol 0.3 mg) for the relief of moderate
          to severe vasomotor symptoms in postmenopausal women
          over a treatment period of 12 weeks."9/07- 8/08.
        • Berlex Pharmaceutical."A Multicenter, randomized, open-label, parallel-group, active control study to evaluate the efficacy and
          safety of LNG IUS (Mirena) as compared to medroxyprogesterone acetate during 6 cycles of treatment in patients with idiopathic menorrhagia."8/06-10/08.
        • UVM Funded Research. Coagulation factors for oral and nonoral contraceptives.
          7/03- 9/08.
        • NIH RO1 AG021476-01.Co-Investigator. "Estrogen Effects on Cholinergic Function in
          Older Women." Primary Investigator: Paul Newhouse, M.D. 7/03 - 6/30/08.
        • Berlex Pharmaceutical. "A multicenter, double-blind, double-dummy, randomized, placebo-controlled study comparing a 2.2 mg 17ß-estradiol/0.69 mg levonorgestrel combination transdermal patch, and a 1 mg 17ß-estradiol transdermal patch with a placebo patch in postmenopausal women to determine the lowest effective dose of estradiol for the relief of moderate to severe hot flushes." 3/05-4/06.
        • Research Initiative. Investigator. "Coagulation Factors on Oral and Transdermal Contraceptives." Co-Investigator: Mary Cushman, M.D. 10/03- 9/05.
        • Wyeth Pharmaceutical."A Phase 3, Multicenter Study to Evaluate the Return to Spontaneous Menses for Subjects Receiving Prior Treatment with a continuous Daily Regimen of Levonorgestrel and Ethinyl Estradiol for Oral Contraception." 1/04-5/05.
        • Wyeth-Ayerst Pharmaceuticals, Inc."A Randomized, Double-Blind, Dose-Ranging Study Of The Safety And Efficacy Of NSP-989 And A Combination Steroid Oral Contraceptive (Desogestrel/Ethinyl Estradiol)." 10/03-2/05.
        • Pharmacia. "Phase III contraception study of Depot Medroxyprogesterone Acetate Subcutaneous Injection (DMPA-SC) in women of childbearing potential in the Americas (including a Bone Mineral Denisty [BMD] substudy comparing the effects of DMPA-SC and DMPA-IM.) Also including a return of ovulation substudy." 5/01-1/05.
        • Wyeth-Ayerst Pharmaceuticals, Inc."A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 ug and Ethinyl Estradiol 20 ug in a Continuous Daily Regimen for Oral Contraception." 2/03-12/04.
        • NIH R01 HL63101. Co-Investigator. "Uterine Vascular Response to Steroid Signaling." Primary Investigator: Ira Bernstein, M.D. 7/99-6/04.
        • Research Initiative.Co-Investigator."T-levels and Sexual Function: Natural Traverse/Menopause." Primary Investigator: Judith Gerber, Ph.D. 10/02-9/03.
        • Wyeth-Ayerst Pharmaceuticals, Inc."A double blind, randomized, placebo- and historical-controlled study of the safety and efficacy of Premarin/Trimegestone for postmenopausal hormone replacement." 1/98-11/02.
        • American College of Obstetricians and Gynecologists/Parke-Davis Research. "The Effect of Hormone Replacement on Cardiovascular Hemodynamics and Blood Volume in Postmenopausal Women with Coronary Artery Disease." 7/98-6/01.
        • Novo-Nordisk Pharmaceuticals Inc."Bleeding Profile with Continuous-Combined Hormone Replacement Therapy:A Randomized, Double-blind, Multicenter, Comparative Trial of 1 mg 17ß estradiol in Combination with 0.25 mg. or 0.5 mg Norethindrone Acetateand Prempro®." 5/98-11/99.
        • NIH PHS U76 PE002601 (M. Reardon)HERSA, Bureau of Health Professions. Area Health Education Center Proposal, University of Vermont College of Medicine. The goal of this project is to provide rural Vermonters with better comprehensive healthcare by placing medical students in medical disciplines throughout Vermont to encourage them to establish a practice in these areas. 9/96-8/99.
        • Genzyme Corporation. "Evaluation of the Safety and Effectiveness of HAL-C Coating Solution in Surgery." 2/92-6/93.
        • Biomedical Research Support Grant. "Oncogene and Growth Factor Expression During Endometrial Development." 9/91-9/92.

        selected publications
        List All   |   Timeline
        1. Marsh WK, Ketter TA, Crawford SL, Johnson JV, Kroll-Desrosiers AR, Rothschild AJ. Progression of female reproductive stages associated with bipolar illness exacerbation. Bipolar Disord. 2012 Aug; 14(5):515-26.
          View in: PubMed
        For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
        Same Department
        Physical Neighbors

        This is an official Page/Publication of the University of Massachusetts Worcester Campus
        Office of the Vice Provost for Research, 55 Lake Ave North, Worcester, Massachusetts 01655
        Questions or Comments? Email: Phone: 508-856-1572